Dr.LipidDallas said:If two explanations both fit, the useful question is which one predicts something the other does not.
Agreed, with the usual condition: that holds for the average and this board is a collection of individuals. A population claim and a personal prediction are different things and get quoted interchangeably.
andrew_nyc said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.
Dr.LipidDallas said:If two explanations both fit, the useful question is which one predicts something the other does not.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.